73. 下垂体性TSH分泌亢進症 TSH-secreting pituitary adenoma Clinical trials / Disease details


臨床試験数 : 1 薬物数 : 3 - (DrugBank : 2) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-173772
22/1/201815/11/2017Phase 3 Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenomaPhase 3, Open-label Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma TSH-secreting pituitary adenomaIntervention name : Lanreotide Acetate
INN of the intervention : Lanreotide
Dosage And administration of the intervention : Deep subcutaneous administration of 60 mg, 90 mg or 120 mg of lanreotide once every 4 weeks.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Teijin Pharma LimitedNULLcomplete20BOTH8Phase 3Japan